CIA
IART icon

Concurrent Investment Advisors’s Integra LifeSciences IART Stock Holding History

Concurrent Investment Advisors’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,943
Closed -$601K – 1036
2024
Q1 		$601K Buy
16,943
+2,500
+17% +$100K 0.02% 495
2023
Q4 		$629K Buy
+14,443
New +$568K 0.03% 437

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Concurrent Investment Advisors's IART Position: Q2 2024 in Review

Concurrent Investment Advisors sold out of Integra LifeSciences (IART) in Q2 2024, closing a stake of 16,943 shares — an estimated $601K sold.

Concurrent Investment Advisors first reported a position in IART in Q4 2023 and held it in 2 quarters. The position peaked at $629K in Q4 2023. 238 funds tracked by Wall St. Rank hold IART as of Q2 2024.

  • Concurrent Investment Advisors reported no remaining Integra LifeSciences position as of Q2 2024 after selling out during the quarter.
  • Concurrent Investment Advisors sold 16,943 Integra LifeSciences shares in Q2 2024, an estimated $601K.
  • Concurrent Investment Advisors first reported a position in Integra LifeSciences in Q4 2023 and held it in 2 quarters.
  • Concurrent Investment Advisors's Integra LifeSciences position peaked at $629K in Q4 2023.
  • 238 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2024.

Based on Concurrent Investment Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.